-+ 0.00%
-+ 0.00%
-+ 0.00%
Alpha Tau Medical's Glioblastoma Data Could Redefine How the Street Values This Earnings Call
Share
Listen to the news
Barchart -8.33% Miss Sep 2025 $-0.12 $-0.14 -16.67% Miss Dec 2025 $-0.13 $-0.14 -7.69% Miss Mar 2026 $-0.13 $-0.26 -100.00% Miss

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

DRTS typically reports earnings before market open, meaning Day 0 captures the market's initial reaction during the first trading session after results are released, while Day +1 reflects follow-through momentum.

Earnings Date Day 0 Move Day 0 Range Day +1 Move Day +1 Range
2026-05-18 -$0.33 (-3.19%) $1.00 (9.65%) +$0.65 (+6.48%) $1.10 (10.97%)
2026-03-09 +$0.30 (+4.68%) $0.68 (10.61%) +$0.13 (+1.94%) $0.74 (11.03%)
2025-11-20 -$0.21 (-5.71%) $0.38 (10.33%) +$0.35 (+10.09%) $0.40 (11.53%)
2025-08-11 +$0.17 (+5.01%) $0.18 (5.31%) -$0.31 (-8.71%) $0.45 (12.77%)
2025-05-19 +$0.31 (+11.11%) $0.27 (9.86%) +$0.16 (+5.16%) $0.34 (10.97%)
2025-03-12 +$0.06 (+2.31%) $0.12 (4.52%) -$0.04 (-1.50%) $0.09 (3.38%)
2024-11-19 +$0.00 (+0.00%) $0.06 (2.60%) -$0.00 (-0.22%) $0.05 (2.17%)
2024-08-14 +$0.01 (+0.48%) $0.05 (2.38%) +$0.14 (+6.64%) $0.16 (7.59%)
Avg Abs Move 4.06% 6.91% 5.09% 8.80%

Historical price action around earnings shows significant volatility, with the stock averaging an absolute move of 4.06% on Day 0 and 5.09% on Day +1. The Day 0 range averages 6.91%, while Day +1 sees an even wider 8.80% range, indicating substantial intraday swings as investors digest results.

The direction of moves has been mixed but leans slightly positive on Day +1. The most recent report (May 2026) saw a 3.19% decline on Day 0 followed by a 6.48% rally on Day +1, suggesting initial disappointment gave way to bargain hunting. The November 2025 report showed a similar pattern with a 5.71% Day 0 drop reversing into a 10.09% Day +1 gain. However, the August 2025 report moved 5.01% higher on Day 0 before reversing 8.71% lower on Day +1, demonstrating that follow-through can work in either direction.

Investors should expect meaningful volatility around this release, with historical patterns suggesting moves in the 4-5% range are typical, though individual reports have produced swings exceeding 10%.

Part 2.2: Options Market Expected Move

Metric Value
Expiration Date 08/21/26 (DTE 14)
Expected Move $1.70 (12.92%)
Expected Range $11.46 to $14.86
Implied Volatility 80.12%

The options market is pricing an expected move of 12.92% through the August 21 expiration, significantly higher than the stock's average historical Day 0 move of 4.06% and Day +1 move of 5.09%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction to Q2 results, possibly reflecting heightened uncertainty around revenue delivery and the company's ability to reverse its recent pattern of earnings misses.

Part 3: What Analysts Are Saying

Analyst sentiment on DRTS has improved recently, with the consensus now leaning bullish. The current average recommendation stands at 4.20 (between Buy and Strong Buy), up from 3.80 one month ago. The rating breakdown shows 3 Strong Buy ratings, 0 Moderate Buys, 2 Holds, 0 Moderate Sells, and 0 Strong Sells among the 5 analysts covering the stock.

The shift in sentiment is notable—one month ago the mix included a Strong Sell rating that has since been removed or upgraded, while a Hold rating was added. This suggests analysts are becoming more constructive on DRTS's prospects despite the recent earnings miss.

The consensus price target of $13.50 implies modest 2.7% upside from the current price of $13.14. However, the wide range of targets—from a low of $8.00 to a high of $17.00—reflects significant disagreement about the company's valuation. The high-end target suggests some analysts see potential for 29% upside if DRTS can execute on its commercial strategy, while the low-end target implies 39% downside risk if revenue fails to materialize or losses continue to widen.

Part 4: Technical Picture

DRTS enters earnings with strong technical momentum. The Barchart Technical Opinion currently shows a 100% Buy signal, up from 80% Buy one week ago and matching the 100% Buy reading from one month ago. This maximum-strength buy signal reflects robust near-term momentum as the stock has rallied sharply.

Timeframe Analysis:

  • Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum heading into the earnings release
  • Medium-term (100% Buy): Strong buy signal across the intermediate timeframe suggests the uptrend is well-established beyond just short-term trading
  • Long-term (100% Buy): Maximum buy signal in the longer-term view indicates the stock has built a sustained uptrend across all timeframes

Trend Characteristics: The Maximum strength signal that is Strengthening suggests DRTS is in an exceptionally robust uptrend environment heading into earnings, with momentum accelerating across all timeframes.

The stock is trading at $13.14, positioned above all major moving averages: the 5-day ($12.88), 10-day ($12.30), 20-day ($12.55), 50-day ($11.46), 100-day ($9.82), and 200-day ($7.74).

Period Value Period Value
5-Day MA $12.88 50-Day MA $11.46
10-Day MA $12.30 100-Day MA $9.82
20-Day MA $12.55 200-Day MA $7.74

This alignment above all moving averages is a classically bullish setup, with the stock showing 70% gains above its 200-day moving average. The technical picture is unambiguously supportive heading into earnings, though the magnitude of the recent rally—the stock is up over 170% year-to-date—means expectations may be elevated. Any disappointment on revenue or guidance could trigger profit-taking given how extended the move has become. Key support on a pullback would likely emerge at the 20-day moving average around $12.55, with stronger support at the 50-day near $11.46.

This article was generated using Barchart’s automated content technology and existing data APIs. As a result, we are able to provide readers with timely, actionable, in-depth analysis on more equities, allowing them to make more informed decisions. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here. And, if you would like to report any inaccuracies, please contact news@barchart.com.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending